2019.May.06
Letter received from National Medical Products Administration (NMPA) of China regarding Adagloxad Simolenin (OBI-822) Phase III clinical study to be resubmitted after supplementation
Date of occurrence of the event: May 06, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: Official letter was received from National Medical Products Administration (NMPA) of China regarding the request for clearance of Phase III clinical study […]
This article is password protected.
To view the content, please enter your password in the field below